ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.

I-Tsang Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.